pharma · Friedreich Ataxia · LRMR
Larimar Therapeutics
Larimar Therapeutics is a pharma organization headquartered in Bala Cynwyd, USA. It trades on NYSE under ticker LRMR. Primary therapeutic focus areas include Friedreich Ataxia. NovaPharmaNews links 3 clinical program(s),
Bala Cynwyd, USA HQ
2016 Founded
82 Employees
Public company Type
LRMR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Bala Cynwyd, USA
- Founded
- 2016
- Employees
- 82
- Programs
- 3
- Drugs
- 2
- Patents
- 5
Nomlabofusp
Phase 1 · small molecule · Friedreich Ataxia
Nomlabofusp for Friedreich Ataxia is a Phase 1 program (small_molecule) at Larimar Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CLIN-1601-103
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Larimar Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Friedreich Ataxia
- Status
- terminated
- Trials
- 1